This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gelband, C. H. Articles by Raizada, M. K. Search for Related Content PubMed PubMed Citation Articles by Gelband, C. H. Articles by Raizada, M. K. Related Collections ACE/Angiotension receptors Cell signalling/signal transduction Functional genomics Hypertension - basic studies Physiological and pathological control of gene expression Gene therapy Genetics of cardiovascular disease

(Circulation Research. 2000;87:1118.)
© 2000 American Heart Association, Inc.

MiniReview

Current Perspectives on the Use of Gene Therapy for Hypertension

Craig H. Gelband, Michael J. Katovich, Mohan K. Raizada

From the Department of Physiology, College of Medicine (C.H.G., M.K.R.) and Department of Pharmacodynamics, College of Pharmacy (M.J.K.), University of Florida, Gainesville, Fla.

Correspondence to Craig H. Gelband, PhD, Department of Physiology, University of Florida College of Medicine, PO Box 100274, Gainesville, FL 32610-0274. E-mail gelband{at}phys.med.ufl.edu

	Abstract

Top Abstract Introduction Gene Therapy for Systemic... Gene Therapy for Pulmonary... Future Directions and... References

 
Abstract—Systemic hypertension is a pathophysiological state that is manifested as high blood pressure and is a major risk factor for stroke, ischemic heart disease, peripheral vascular disease, and progressive renal damage. Pulmonary hypertension occurs in 3 distinct forms: primary pulmonary hypertension, pulmonary hypertension of the newborn, or secondary pulmonary hypertension attributable to a variety of lung and cardiovascular diseases. This review discusses the use of gene therapy in the control of systemic and pulmonary hypertension. Overexpression of vasodilator genes as well as antisense knockdown of vasoconstrictor genes has been successfully used in animal models of both forms of hypertension. Furthermore, the use of viral vectors to deliver these constructs has achieved long-term control of hypertension. The successful establishment of gene therapy techniques in the animal models of hypertension coupled with the anticipated advances in the genetic aspects of this disease would make it highly feasible to attempt gene delivery in the control of human hypertension.

Key Words: antisense • gene therapy • hypertension • renal and cardiac pathophysiology • renin-angiotensin system

	Introduction

Top Abstract Introduction Gene Therapy for Systemic... Gene Therapy for Pulmonary... Future Directions and... References

 
Systemic hypertension is a complex pathophysiological state that is primarily manifested as chronic high blood pressure. If unchecked, it is a major risk factor for stroke, ischemic heart disease, peripheral vascular disease, and progressive renal damage.^{1 2 3} It is well established that a hyperactive renin-angiotensin system (RAS) plays a key role in the development and maintenance of human primary hypertension and, by some estimates, contributes to at least 10% to 30% of all cases of hypertension.^{4 5 6} It is not surprising that tremendous efforts have been directed toward the understanding of the RAS and its involvement in the control of blood pressure. The interruption of the RAS attenuates high blood pressure and many pathophysiological aspects of hypertension.^{1 5 7 8 9 10} Also, some genes encoding members of the RAS are associated with hypertension.^{11 12 13 14 15} Thus, it is reasonable to conclude that the RAS is essential in the normal regulation of blood pressure and pathophysiology of systemic hypertension.

Traditional agents such as diuretics, ß-blockers, and calcium-channel antagonists have been used to treat systemic hypertension. Recently, a group of antihypertensive agents targeting the RAS that act by inhibiting either the formation of angiotensin II (Ang II) or the actions of Ang II have been used. These agents are reliable and affordable, and their short duration of action makes them an excellent choice for reversible drugs. However, they are not without limitations and disadvantages. As with most antihypertensive drugs, their effects are short-lived, have to be administered on a regular basis, and produce significant side effects. These limitations have often led to problems with compliance with some patients. Finally, all of the therapeutic agents are excellent in the control of blood pressure but hold little promise in a cure, because discontinuing the drugs results in the reappearance of high blood pressure and related cardiovascular pathophysiological symptoms of the disease.

In addition to systemic hypertension, pulmonary hypertension is a cardiovascular disease with significant morbidity and mortality. In pulmonary hypertension, the mean pulmonary arterial pressure is >20 mm Hg at rest. This disorder occurs in 3 distinct forms: primary pulmonary hypertension, pulmonary hypertension of the newborn, and secondary pulmonary hypertension.¹⁶ The cellular and physiological mechanisms of this form of hypertension are poorly defined; thus, there are few effective pharmacological agents that are used clinically. The drugs presently in use are anticoagulants, calcium-channel antagonists, intravenous prostacyclin, and inhaled nitric oxide; however, none of these agents has significantly reduced the mortality attributable to pulmonary hypertension. From the discussion above it can be concluded that pharmacological regimens have reached a conceptual plateau for the treatment and long-term prevention of hypertension and that a cure for either systemic or pulmonary hypertension is not on the horizon.

For this reason, many investigators have turned their attention to explore a gene therapy strategy.^{17 18} They have argued that genetic manipulation may induce a permanent correction, resulting in a possible cure for hypertension. On a conceptual level, such an approach could offer major advantages over pharmacological therapy. It could essentially eliminate the compliance and side-effect issues when using conventional therapy. In addition, a genetic strategy could lead to a permanent control of hypertension if appropriate target genes controlling hypertension could be identified and their expression could be regulated.

	Gene Therapy for Systemic Hypertension

Top Abstract Introduction Gene Therapy for Systemic... Gene Therapy for Pulmonary... Future Directions and... References

 
Overexpression of Vasodilator Genes
Genes relevant to both vasodilation and vasoconstriction are successful targets for gene therapy in systemic hypertension. Chao and colleagues^{19 20 21 22 23} have reversed systemic hypertension in adult rats by overexpressing the vasodilator genes atrial natriuretic peptide, kallikrein, adrenomedullin, and endothelial nitric oxide synthase (eNOS). They demonstrated that delivery of these genes, either via naked DNA or viral delivery systems, in different rat models of hypertension (spontaneously hypertensive rat [SHR], Dahl salt-sensitive rat, deoxycorticosterone acetate–treated rat, and Goldblatt hypertensive rat) results in a lowering of blood pressure that is transient in nature, lasting anywhere from 6 to 12 weeks. Specifically, in the above models, the overexpression of kallikrein, atrial natriuretic peptide, adrenomedullin, and eNOS caused a 22 to 50, 22, 28, and 21 mm Hg change in blood pressure, respectively, over a period of 6 to 12 weeks after delivery. This decrease in blood pressure is accompanied by a transient attenuation of some pathophysiological changes observed in the major target organs (heart, kidney, and blood vessels) associated with hypertension.

Antisense Knockdown of the RAS
The use of antisense gene therapy to target vasoconstrictor pathways has been quite successful in lowering blood pressure and preventing or reversing the associated cardiovascular pathophysiology of hypertension on a long-term basis. The RAS has been the target of choice for antisense gene therapy in the treatment of systemic hypertension. There are multiple reasons for this. First, the role of the RAS in hypertension is well understood. Second, the RAS provides an ideal target for gene delivery, because it is widely distributed. Third, pharmacological agents that target the RAS exert antihypertensive effects at multiple levels (vasodilator mechanisms and fibrinolytic and oxidative stress pathways) in addition to their actions on Ang II.¹⁷

Conceptual support that antisense targeting of the RAS would be effective in treating hypertension was derived from the use of antisense oligonucleotides.^{24 25 26} Studies demonstrated that the central or peripheral injection of antisense oligonucleotides to the RAS (angiotensinogen or angiotensin II type 1 receptor [AT₁R]) resulted in a transient, short-term (days), and modest, but significant, effect on lowering blood pressure in the SHR. The amount (23 mm Hg) and duration (9 weeks) of the blood pressure–lowering effect were prolonged to weeks with the use of an adeno-associated virus viral vector delivery system.²⁷

Our research group has used these studies as a basis to determine if retroviral-vector–mediated delivery of antisense targeting the AT₁R and angiotensin-converting enzyme (ACE) would prevent hypertension (high blood pressure) and cardiovascular pathophysiology associated with hypertension for longer time periods.^{17 28 29 30} A single intracardiac administration of retroviral particles containing AT₁R antisense (AT₁R-AS) into 5-day-old SHR results in attenuation of high blood pressure and long-term expression of the AT₁R-AS for at least 210 days. This attenuation of blood pressure is similar to that seen for AT₁R antagonists. This was associated with complete attenuation of cardiac hypertrophy, arterial wall thickness, and perivascular and myocardial fibrosis. AT₁R-AS expression also resulted in significant reduction in the amount of neointimal formation after carotid artery balloon injury in the SHR (Figure). AT₁R-AS prevented alterations in vascular reactivity, endothelial dysfunction, Ca²⁺ handling, and ion channel dysfunction in renal arterioles. These studies established that AT₁R-AS will abolish the development of hypertension in the SHR on a long-term basis.

View larger version (42K): [in this window] [in a new window]   Figure 1. Effect of AT1R-AS on vascular growth after carotid artery balloon injury in the SHR. Top, AT1R-AS and losartan inhibit neointima formation after arterial balloon injury. Bar=70 µm. Bottom, Mean effect of AT1R-AS (n>5, *P<0.05).

Intracardiac injection of virus particles containing AT₁R-AS into the adult SHR resulted in a 30- to 60-mm Hg reduction in blood pressure that was maintained for up to 36 days compared with the SHR treated with virus alone.³¹ This was accompanied by a reversal of the increase in vasoreactivity and the gain of endothelial function in renal resistance arterioles. These observations are consistent with studies that have previously shown a similar transient reversal of high blood pressure by antisense in the adult rat.^{24 25 26 27} Collectively, these data demonstrate that virally mediated gene delivery of AT₁R-AS can effectively reduce blood pressure and reverse renovascular pathophysiology associated with hypertension in the adult SHR. However, the transient nature of the antihypertensive effect in the adult remains to be addressed and must be improved on.

Also relevant would be determining if antisense gene targeting could clarify the role of the tissue RAS in cardiovascular pathophysiology. This is clinically relevant in view of the recent results from the Heart Outcomes Prevention Evaluation clinical study.³² This study showed that ramipril, an ACE inhibitor, produced a significant improvement in outcomes and reduction in deaths attributable to cardiovascular causes without a significant change in blood pressure. Introduction of ACE antisense (ACE-AS) by a retroviral vector resulted in a modest (15 to 18 mm Hg) but significant attenuation of high blood pressure exclusively in the SHR for 100 days.^{33 34} In spite of this modest decrease in blood pressure, ACE-AS resulted in complete attenuation of ventricular hypertrophy and prevention of altered endothelial function, vascular reactivity, [Ca²⁺]_i, and ion channel dysfunction. The data provide support for the importance of the tissue RAS emphasized in the results of the Heart Outcomes Prevention Evaluation trial.

In summary, the above data illustrate that an interruption of the RAS activity at a genetic level could prevent hypertension on a long-term basis. Support for this hypothesis is provided by several experiments. The F₁ and F₂ generation offspring of the AT₁R-AS–treated SHRs expressed a persistently lower blood pressure, decreased cardiac hypertrophy and fibrosis, decreased medial thickness, and normalization of renal artery excitation-contraction coupling, Ca²⁺ current, membrane potential, K_v current, and [Ca²⁺]_i compared with offspring derived from the virus-treated SHRs.³⁰ In addition, AT₁R-AS was found in the genomic DNA and was expressed in cardiovascularly relevant tissue of the F₁ and F₂ offspring. The transmission of antihypertensive phenotypes to the offspring was also seen in the ACE-AS–treated SHRs.^{33 34} The mechanism of transmission of this antihypertensive phenotype to the offspring is unknown at the present time but might involve germ line transmission of the antisense, parental environment, transmission of a humoral factor through the breast milk, or expression at a critical stage of SHR development.^{35 36 37 38 39} For example, cross studies have shown that SHR babies parented by WKY mothers express a significantly lower blood pressure, while WKY babies parented by SHR mothers are hypertensive.^{36 37}

Antisense Knockdown of the ß₁-Adrenergic Receptors
Zhang et al⁴⁰ have used antisense oligonucleotides to the ß₁ receptor to provide additional conceptual support for gene therapy in hypertension. A single intravenous injection of ß₁ receptor antisense in cationic liposomes decreased cardiac ß₁ receptor density by 30% to 50%, attenuated the ß₁ receptor–mediated positive inotropic response in isolated perfused hearts, and decreased blood pressure by 38 mm Hg in the SHR. The effect lasted 2 to 3 weeks and, interestingly, had no significant effect on heart rate. In addition, a 35% reduction in the renal ß₁ but not ß₂ receptor density was observed. Finally, 4 days after administration, ß₁ receptor antisense decreased preprorenin mRNA levels in the renal cortex by 37%, which was accompanied by a marked diminution of plasma renin activity and plasma Ang II levels by day 10.⁴¹

	Gene Therapy for Pulmonary Hypertension

Top Abstract Introduction Gene Therapy for Systemic... Gene Therapy for Pulmonary... Future Directions and... References

 
It has only been in the last 2 years that gene therapy for treatment of pulmonary hypertension has begun. The overexpression of vasodilator genes, eNOS, prepro-calcitonin gene–related peptide (CGRP), and prostaglandin I synthase (PGIS) has shown great promise in the laboratory for treatment of pulmonary hypertension. Patients with severe pulmonary hypertension have a PGIS deficiency of their precapillary vessels, but the importance of this deficiency for lung vascular remodeling remains unclear. Geraci et al⁴² hypothesized that selective pulmonary overexpression of PGIS may prevent the development of pulmonary hypertension. Transgenic mice were created with selective pulmonary PGIS overexpression. The mice overexpressing PGIS produced 2-fold more pulmonary 6-keto prostaglandin F₁ than controls, and, after exposure to chronic hypobaric hypoxia, the PGIS-overexpressing mice showed a lower right ventricular systolic pressure than controls. Histological examination of the lungs revealed nearly normal arteriolar vessels in the PGIS-expressing mice in comparison with vessel-wall hypertrophy in the control mice. These studies demonstrate that overexpression of PGIS in the lung protected mice from the development of pulmonary hypertension after exposure to chronic hypoxia.

Using adenoviral gene transfer of eNOS to the mouse lung, Champion et al⁴³ showed the beneficial effects of this gene on pulmonary hemodynamics. At 21 to 28 days after gene transfer, the pressure-flow relationship in the pulmonary vascular bed was shifted to the right in animals transfected with eNOS, and pulmonary pressor responses to endothelin-1, Ang II, and ventilatory hypoxia were reduced significantly in animals transfected with the eNOS gene. In preliminary findings, this same group demonstrated that not only did the eNOS knockout mouse have pulmonary hypertension (pulmonary artery pressure 25 mm Hg), but when the eNOS gene was delivered back to the lung of the knockout mouse using an adenoviral construct, no pulmonary hypertension developed in the knockout.⁴⁴ CGRP is also believed to play an important role in maintaining low pulmonary vascular resistance and modulating pulmonary vascular responses to chronic hypoxia. Intratracheal administration of prepro-CGRP with an adenovirus to the mouse lung, followed by 16 days of chronic hypoxia, caused an attenuation of the hypoxic-induced increases in pulmonary vascular resistance, right ventricular mass, pulmonary artery pressure, and pulmonary vascular remodeling.⁴⁵ These recent findings suggest that the use of gene therapy targeting vasodilator agents in the lung may be successful in the treatment of pulmonary hypertension.

	Future Directions and Conclusions

Top Abstract Introduction Gene Therapy for Systemic... Gene Therapy for Pulmonary... Future Directions and... References

 
It is evident from the above discussion that the use of gene therapy is an exciting approach that is intellectually sound and, on the basis of animal experiments, may hold great promise for a permanent treatment of hypertension. However, before leaping to the next step (eg, clinical trials), several important issues must be resolved and hurdles must be cleared. First, are the viral vectors the most effective means to deliver an antihypertensive gene? Benefit versus risk consideration of viral vectors may lead us to compromise and develop better means to deliver more effective and highly stable naked DNA that will have prolonged duration of action of desired effects. However, if viral vectors are the method of choice, they must meet strict safety requirements. For example, it would be imperative that the integrations site of the viral vector in the genome be known and that its influence on neighboring genes be evaluated and proven to be free of immune and other adverse side effects.

Second, other gene targets that may be relevant in hypertension must be explored. For example, the targeting of matrix proteins could be a potentially interesting site of gene therapy for hypertension. This is relevant in view of the fact that therapies using secreted molecules may not require as high a degree of transduction as do therapies that require intracellular expression of proteins or antisense. Cowan et al⁴⁶ showed that progression of pulmonary hypertension is associated with increased serine elastase activity and the proteinase-dependent deposition of tenascin-C. In monocrotaline-treated rats, oral administration of serine elastase inhibitors increased survival and decreased pulmonary artery pressure and muscularization. This was attributable to myocyte apoptosis and loss of extracellular matrix, specifically elastin and tenascin-C. Therefore, it seems plausible that targeting extracellular matrix proteins may also be beneficial in vascular disorders. It would also be interesting to develop a strategy that would target antisense knockdown of Ca²⁺ channels using a smooth muscle cell–specific promoter. Finally, cell-specific overexpression of signaling molecules that may be vasodilator in nature (ie, protein kinases A and G) would be potential targets for antihypertensive gene therapy.

In conclusion, there is sufficient evidence to indicate that gene therapy may be an important and significant step forward in the long-term treatment and possible cure of both systemic and pulmonary hypertension. It is quite possible that hypertension-relevant genes could be identified in the near future. The establishment of the conceptual basis for gene therapy in the animal models of hypertension coupled with the anticipated advances in the genetic aspects of this disease would make it highly feasible to attempt gene delivery in the control of human hypertension

	Acknowledgments

 
This work was supported by National Institutes of Health grants HL-52189 (to C.H.G.) and HL-56921 (to M.K.R. and M.J.K.) and by the American Heart Association, Florida Affiliate.

Received June 29, 2000; revision received October 18, 3000; accepted October 18, 2000.

	References

Top Abstract Introduction Gene Therapy for Systemic... Gene Therapy for Pulmonary... Future Directions and... References

 

1. Elkind MS, Sacco RL. Stroke risk factors and stroke prevention. Semin Neurol. 1998;18:429–440.[Medline] [Order article via Infotrieve]
2. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med. 1993;153:598–615.[Abstract]
3. Hall WD. Risk reduction associated with lowering systolic blood pressure: review of clinical trial data. Am Heart J. 1999;138:225–230.[Medline] [Order article via Infotrieve]
4. Rothermund L, Paul M. Hypertension and the renin-angiotensin system: evidence from genetic and transgenic studies. Basic Res Cardiol. 1998;93:1–6.[Medline] [Order article via Infotrieve]
5. Stroth U, Unger T. The renin-angiotensin system and its receptors. J Cardiovasc Pharmacol. 1999;33:21–28.
6. Cody RJ. The integrated effects of angiotensin II. Am J Cardiol. 1997;79:9–11.[Medline] [Order article via Infotrieve]
7. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med. 1993;153:937–942.[Abstract]
8. Yamazaki T, Yazaki Y. Role of tissue angiotensin II in myocardial remodelling induced by mechanical stress. J Hum Hypertens. 1999;13:S43–S47.
9. Hall JE, Brands MW, Henegar JR. Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. J Am Soc Nephrol. 1999;10:258–265.
10. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992;71:169–180.[Medline] [Order article via Infotrieve]
11. Schunkert H. Polymorphism of the angiotensin-converting enzyme gene and cardiovascular disease. J Mol Med. 1997;75:867–875.[Medline] [Order article via Infotrieve]
12. Berglund L. A recurrent theme with a new spin: ACE polymorphism and cardiovascular disease. J Lab Clin Med. 1998;131:485–486.[Medline] [Order article via Infotrieve]
13. Rapp JP, Wang SM, Dene H. A genetic polymorphism in the renin gene of Dahl rats cosegregates with blood pressure. Science. 1989;243:542–544.[Abstract/Free Full Text]
14. Jacob HJ, Lindpaintner K, Lincoln SE, Kusumi K, Bunker RK, Mao YP, Ganten D, Dzau VJ, Lander ES. Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat. Cell. 1991;67:213–224.[Medline] [Order article via Infotrieve]
15. Deng AY, Dene H, Rapp JP Mapping of a quantitative trait locus for blood pressure on rat chromosome 2. J Clin Invest. 1994;94:431–436.
16. Wanstall JC, Jeffery TK. Recognition and management of pulmonary hypertension. Drugs. 1998;56:989–1007.[Medline] [Order article via Infotrieve]
17. Raizada MK, Katovich MJ, Berecek K, Wang H, Gelband CH. Is antisense gene therapy a step in the right direction in the control of hypertension? Am J Physiol. 1999;46:H423–H432.
18. Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. Pharmacol Ther. 1998;80:35–47.[Medline] [Order article via Infotrieve]
19. Chao J, Chao L. Experimental kallikrein gene therapy in hypertension, cardiovascular and renal diseases. Pharmacol Res. 1997;35:517–522.[Medline] [Order article via Infotrieve]
20. Lin KF, Chao L, Chao J. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension. 1997;30:307–313.[Abstract/Free Full Text]
21. Chao J, Jin L, Lin KF, Chao L. Adrenomedullin gene delivery reduces blood pressure in spontaneously hypertensive rats. Hypertens Res. 1997;20:2692–2677.
22. Lin KF Chao J, Chao L. Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt-sensitive rats. Hum Gene Ther. 1998;9:1429–1438.[Medline] [Order article via Infotrieve]
23. Dobrzynski E, Yoshida H, Chao J, Chao L. Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats. Immunopharmacology. 1999;44:57–65.[Medline] [Order article via Infotrieve]
24. Gyurko R, Wielbo D, Phillips MI. Antisense inhibition of AT₁ receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul Pept. 1993;49:167–174.[Medline] [Order article via Infotrieve]
25. Tomita N. Morishita R, Higaki J, Aoki M, Nakamura Y, Mikami H, Fukamizu A, Murakami K, Kaneda Y, Ogihara T. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. Hypertension. 1995;26:131–136.[Abstract/Free Full Text]
26. Makino N, Sugano M, Ohtsuka S, Sawada S. Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats. Hypertension. 1998;31:1166–1170.[Abstract/Free Full Text]
27. Phillips MI, Mahuczy-Dominiak D, Coffey M, Galli SM, Kimura B, Wu P, Zelles T. Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT₁R mRNA antisense. Hypertension. 1997;29:374–380.[Abstract/Free Full Text]
28. Martens JR, Reaves PY, Lu D, Berecek KH, Bishop SP, Katovich MJ, Raizada MK, Gelband CH. Prevention of cardiac and renovascular pathophysiological changes in hypertension by AT₁ receptor antisense gene therapy. Proc Natl Acad Sci U S A. 1998;95:2664–2669.[Abstract/Free Full Text]
29. Gelband CH, Reaves PY, Evans J, Wang H, Katovich MJ, Raizada MK. Angiotensin II type 1 receptor antisense gene therapy prevents altered renal vascular calcium homeostasis in hypertension.Hypertension. 1999;33:360–365.[Abstract/Free Full Text]
30. Reaves PY, Gelband CH, Wang H, Lu D, Berecek KH, Yang H, Katovich MJ, Raizada MK. Permanent prevention of hypertension by angiotensin II type 1 receptor antisense gene therapy. Circ Res. 1999;86:e44–e50.
31. Katovich MJ, Gelband CH, Reaves PY, Wang H, Raizada MK. Reversal of hypertension by angiotensin II type 1 receptor antisense gene therapy in the adult SHR. Am J Physiol. 1999;46:H1260–H1264.
32. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153.[Abstract/Free Full Text]
33. Gelband CH, Wang H, Gardon ML, Keene K, Goldberg DS, Reaves PY, Katovich MJ, Raizada MK. ACE antisense prevents altered renal vascular reactivity, but not high blood pressure, in the SHR. Hypertension. 2000;35:209–213.[Abstract/Free Full Text]
34. Wang H, Reaves PY, Gardon ML, Keene K, Goldberg DS, Gelband CH, Katovich MJ, Raizada MK. Transmission of antihypertensive effects of ACE antisense gene therapy from parents to offspring. Hypertension. 2000;35:208–212.
35. Heckmann U, Ottens E, Zidek W, Vetter H. A circulating hypertensive factor in primary hypertension: effect of antihypertensive therapy. Nephron. 1987;47:138–141.
36. Zidek W, Ottens E, Heckmann U. Transmission of hypertension in rats by cross circulation. Hypertension. 1989;14:61–65.[Abstract/Free Full Text]
37. McMurtry JP, Wright GL, Wexler BC. Spontaneous hypertension ion cross-suckled rats. Science. 1981;211:1173–1175.[Abstract/Free Full Text]
38. McCarty R, Lee JH. Maternal influences on adult blood pressure of SHRs: a single pup cross-fostering study. Physiol Behav. 1996;59:71–77.[Medline] [Order article via Infotrieve]
39. Berecek KH, Schwertschlag U, Gross F. Alterations in renal vascular resistance and reactivity in spontaneous hypertension of rats. Am J Physiol. 1980;238:H287–H293.
40. Zhang YC, Bui JD, Shen L, Phillips MI. Antisense inhibition of ß₁-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats. Circulation. 2000;101:682–688.[Abstract/Free Full Text]
41. Zhang YC, Kimura B, Shen L, Phillips MI. New ß-blocker: prolonged reduction in high blood pressure with ß₁ antisense oligodeoxynucleotides. Hypertension. 2000;35:219–224.[Abstract/Free Full Text]
42. Geraci MW, Gao B, Shepherd DC, Moore MD, Westcott JY, Fagan KA, Alger LA, Tuder RM, Voelkel NF. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest. 1999;103:1509–1515.[Medline] [Order article via Infotrieve]
43. Champion HC, Bivalacqua TJ, D’Souza FM, Ortiz LA, Jeter JR, Toyoda K, Heistad DD, Hyman AL, Kadowitz PJ. Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo: effect on agonist-induced and flow-mediated vascular responses. Circ Res. 1999;84:1422–1432.[Abstract/Free Full Text]
44. Champion HC, Bivalacqua TJ, Greenberg SS, Giles TD, Heistad DD, Hyman AL, Kadowitz PJ. Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo: selective rescue of pulmonary hypertension in eNOS-deficient mice. Circulation. 1999;100:I-28.
45. Champion HC, Bivalacqua TJ, Toyoda K, Heistad DD, Hyman AL, Kadowitz PJ. In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse. Circulation. 2000;101:923–930.[Abstract/Free Full Text]
46. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med. 2000;6:698–702.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				J.-C. Richard, Z. Zhou, D. E. Ponde, C. S. Dence, P. Factor, P. N. Reynolds, G. D. Luker, V. Sharma, T. Ferkol, D. Piwnica-Worms, et al. Imaging Pulmonary Gene Expression with Positron Emission Tomography Am. J. Respir. Crit. Care Med., May 1, 2003; 167(9): 1257 - 1263. [Abstract] [Full Text] [PDF]

				Y. Chu, S. Iida, D. D. Lund, R. M. Weiss, G. F. DiBona, Y. Watanabe, F. M. Faraci, and D. D. Heistad Gene Transfer of Extracellular Superoxide Dismutase Reduces Arterial Pressure in Spontaneously Hypertensive Rats: Role of Heparin-Binding Domain Circ. Res., March 7, 2003; 92(4): 461 - 468. [Abstract] [Full Text] [PDF]

				K Taylor and J Stein Dyslexia and familial high blood pressure: an observational pilot study Arch. Dis. Child., January 1, 2002; 86(1): 30 - 33. [Abstract] [Full Text] [PDF]

				A. S. Pachori, M. J. Huentelman, S. C. Francis, C. H. Gelband, M. J. Katovich, and M. K. Raizada The Future of Hypertension Therapy: Sense, Antisense, or Nonsense? Hypertension, February 1, 2001; 37(2): 357 - 364. [Abstract] [Full Text] [PDF]

				S. C. FRANCIS, M. K. RAIZADA, A. A. MANGI, L. G. MELO, V. J. DZAU, P. R. VALE, J. M. ISNER, D. W. LOSORDO, J. CHAO, M. J. KATOVICH, et al. Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb? Physiol Genomics, December 21, 2001; 7(2): 79 - 94. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gelband, C. H. Articles by Raizada, M. K. Search for Related Content PubMed PubMed Citation Articles by Gelband, C. H. Articles by Raizada, M. K. Related Collections ACE/Angiotension receptors Cell signalling/signal transduction Functional genomics Hypertension - basic studies Physiological and pathological control of gene expression Gene therapy Genetics of cardiovascular disease